GlaxoSmithKline plc, Mylan N.V. and Apotex Inc. are Dominating the U.S. HSV1 Treatment Market in 2019

The U.S. HSV1 Treatment Market is expected to grow with the CAGR of 11.9% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/us-hsv1-treatment-market

The U.S. HSV1 treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in the U.S. HSV1 treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This helped the companies to maximize the sales with enhanced product portfolio. For instance, in February 2020, Bausch Health Companies Inc. launched a new telemedicine platform on dermatology.com in the U.S. This website launch allows patients to consult with healthcare and physicians in order to receive prescription on demand for various dermatology products such as aldara, solodyn. Aldara is an imiquimod cream which is used for HSV1 treatment. This program launched helps the company to gain patients attention and also to increase awareness towards major HSV1 treatment products.

GlaxoSmithKline plc is the dominating player in the U.S. HSV1 treatment market. The other key players existing in the market includes Apotex Inc., Mylan N.V., Cipla Inc., Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Avet Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Tolmar Pharmaceuticals, Inc., Perrigo Company plc, Ortho Dermatologics' (A Part of Bausch Healthcare Companies Inc.), F. Hoffmann-La Roche Ltd., Macleods Pharmaceuticals Ltd., Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG), Dr. Reddy’s Laboratories Ltd., EXCELL BIOTECH, NANOVIRICIDES, INC., Glenmark Pharmaceutical Inc., USA (A Subsidiary of Glenmark Pharmaceuticals Ltd.), X-Vax Technology, Inc., AiCuris GmbH & Co. KG, Mustang Bio (A Subsidiary of Fortress Biotech, Inc.), and Sorrento Therapeutics, Inc. among others.

GlaxoSmithKline plc:

GlaxoSmithKline plc headquartered in Middlesex, U.K. was incorporated in 1715. The company focuses on manufacturing and developing vaccines, prescription medicines, health related consumer products among others. The company deals in various business segments such as pharmaceuticals, vaccines & consumer healthcare among which pharmaceuticals is the market focused segment. The products offered by the company fall in various categories such as our prescription medicines, our vaccines, our consumer healthcare products, ViiV healthcare and stiefel dermatology among which the market focused products falls under our prescription medicines category.

For instance,

  • In May 2020, GlaxoSmithKline plc officially announced the partnership with Samsung Biologics for better pharmaceutical portfolio. This will enhance and expand the portfolio of the company and will lead to more revenue generation from the product line.

The company has a wide presence across the globe in North America, South America, Europe, Asia-Pacific, and Middle East & Africa. The company generates revenue through various subsidiary companies such as Action Potential Venture Capital Limited (England), Adechsa GmbH (ii) (Switzerland), Affymax Research Institute (U.S.), Allen Farmaceutica, S.A. (Spain) among others.

Mylan N.V.:

Mylan N.V. headquartered in Pennsylvania, U.S. was incorporated in 1761. The company focuses on specialty and generic pharmaceuticals and manufactures ingredients for allergy, and respiratory problems among others. The products offered by the company fall in various categories such as biosimilars, generics, brand, over-the-counter, and API among which the market focused products falls under generics category.

For instance,

  • In May 2020, Mylan N.V. was at virtual healthcare global conference, and they presented the investor relations. This helped them to reach more healthcare professionals across the regions through online portal in this pandemic.

The company has a wide presence across the globe in North America, South America, Europe, Asia-Pacific, and Middle East & Africa. The company generates revenue through various subsidiary companies such as Agila Australasia Pty Ltd (Australia), Alphapharm Pty. Ltd. (Australia), Mylan Australia Holding Pty Ltd. (Australia), Mylan Australia Pty Limited (Australia) among others.

Apotex Inc.:

Apotex Inc. headquartered in Florida, U.S. was incorporated in 1974. The company focuses on manufacturing of the pharmaceutical products, injectable products, and specialty products among others. The products offered by the company fall in various categories such as all products, new products, unit dose products, injectable products and specialty products among which the market focused products falls under all products category.

For instance,

  • In March 2017, Apotex Inc. announced USD 184.00 million investments for the development of advanced manufacturing and R&D center in the U.S. This initiative has helped the company to increase production of drugs leading to more revenue generation.

The company has a wide presence across the globe in North America and Asia-Pacific.